Quantum BioPharma Moves to Lead Class Action Over Alleged Stock Manipulation by Canadian Banks

An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.

Quantum BioPharma says it understands that shareholder Paul Durkacz has filed a class action lawsuit against Canadian banks CIBC and RBC, alleging that Quantum BioPharma investors were victims of illegal stock manipulation between January 2021 and October 2025, causing significant harm to shareholders who sold their securities in that period. The company intends to seek appointment as a lead plaintiff in the case to help protect its shareholder base, a move that could position it as an active litigant in a high-profile challenge to major financial institutions; separately, Quantum BioPharma has renewed the services of LWM for one month starting December 22, 2025, underscoring its continued focus on communications as it pursues both its core drug development programs and its broader strategic and litigation initiatives.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company focused on innovative assets and biotech solutions targeting neurodegenerative and metabolic disorders as well as alcohol misuse disorders, with drug candidates in various stages of development. Through its wholly owned subsidiary Lucid Psycheceuticals, the company is advancing Lucid-MS, a patented new chemical entity that has shown an ability in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum BioPharma also invented unbuzzd™ and retains an equity stake and royalty rights in Unbuzzd Wellness Inc., while keeping full rights to develop related pharmaceutical and medical products, and it maintains a portfolio of strategic, property-secured investments via its FSD Strategic Investments subsidiary.

Average Trading Volume: 4,671

Technical Sentiment Signal: Sell

Current Market Cap: C$43.7M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.